Catalyst Wire Dossier Catalyst Wire Dossier

Convidecia (Ad5-nCoV)

Adenovirus type-5 vector-based COVID-19 vaccine · CanSino Biologics
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Convidecia (Ad5-nCoV), covering 2025-02-21 to 2025-02-21. Get the full timeline:

Most recent: Clinical Trial Update: Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine [Phase 1, Phase 2]

See pricing